X0306 4 2018-03-19 0 0001314102 pSivida Corp. PSDV 0001450485 Lurker Nancy C/O PSIVIDA CORP. 480 PLEASANT STREET WATERTOWN MA 02472 1 1 0 0 President & CEO Common stock 2018-03-19 4 A 0 38333 0.00 A 95033 D On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 19,166 shares representing a previously granted performance stock unit award vested on that date. An additional 19,167 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. /s/ John Mercer, Attorney-in-Fact 2018-03-21